EA
CBAY

Emerald Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Emerald Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,068,661
Closed -$25.2M – 265
2023
Q4 		$25.2M Buy
1,068,661
+84,886
+9% +$1.51M 1.08% 27
2023
Q3 		$14.7M Buy
+983,775
New +$13M 0.71% 61

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Emerald Advisers's CBAY Position: Q1 2024 in Review

Emerald Advisers sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,068,661 shares — an estimated $25.2M sold.

Emerald Advisers first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $25.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Emerald Advisers reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Emerald Advisers sold 1,068,661 Cymabay Therapeutics shares in Q1 2024, an estimated $25.2M.
  • Emerald Advisers first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
  • Emerald Advisers's Cymabay Therapeutics position peaked at $25.2M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Emerald Advisers's 13F filing for Q1 2024, filed 8 May 2024.